KRAS and cancer: The activity of the Hippo pathway transcription factors substitutes for the activity of oncogenic KRAS G12C in cancer cells treated with inhibitors of KRAS, leading to treatment resistance through activation of the PI3K/AKT cascade and MYC activation [72].